No Big Dose of Consolidation: Dr. Reddy’s MD Predicts Slow Merger Activity!

Dr Reddy's Laboratories CEO GV Prasad has stated that major mergers and acquisitions in Indian pharma in the near term are doubtful given global uncertainties. Although generic business has not been smooth, Dr Reddy's has reached FY24 revenue of ₹28,000 crore and is eyeing constructing sustainable f...

Dr Reddy's Laboratories CEO GV Prasad has stated that major mergers and acquisitions in Indian pharma in the near term are doubtful given global uncertainties. Although generic business has not been smooth, Dr Reddy's has reached FY24 revenue of ₹28,000 crore and is eyeing constructing sustainable franchises and constructing the portfolio into branded generics, consumer health, and OTC businesses. Prasad cited India's growing healthcare market driven by rising income levels and the necessity for better disease detection and treatment. He also expressed optimism over India's role in obesity drug development in the future with a caution on potential side effects. Dr Reddy's is leveraging partnerships and technology to establish its strength in Russia, Europe, Brazil, and China, which are the focus markets. The drug industry's market leader is dedicated to innovation while conforming to changing industry dynamics. Source: Economic Times, M&A Critique